CD44 and prostate carcinoma: In this study, we established an experimental therapeutic platform of cellular immunotherapy targeting for PCSCs based on the cytokine-induced killer T cells specifically activated by dendritic cells (DC-CIK) which had been preloaded or sensitized with immunogenic peptides derived from two PCSC-associated membrane antigens, CD44 and epithelial cell adhesion molecule (EpCAM or CD326), and both have been utilized as potential therapeutic targets via different approaches for prostate cancer.